Ovid Therapeutics GAAP EPS of -$0.17 beats by $0.04

Nov. 08, 2022 8:57 AM ETOvid Therapeutics Inc. (OVID)By: Niloofer Shaikh, SA News Editor
  • Ovid Therapeutics press release (NASDAQ:OVID): Q3 GAAP EPS of -$0.17 beats by $0.04.
  • Revenue of $11.1K.
  • The company ended Q3 with cash, cash equivalents and marketable securities of $137.9M, which is expected to support the advancement of Ovid's epilepsy pipeline into 2025

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.